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Like the innate antibodies she stud-
ies, Nicole Baumgarth acts fast in the 
face of adversity. When she wasn't al-
lowed to enroll in the African live-
stock program that she had her heart 
set on in college, Baumgarth switched 
to mice. When Reagan was elected, 
she opted for the post-doc in Austra-
lia. When a car hit her bicycle soon 
after moving to the US for a second 
post-doc, she didn’t head home de-
feated. Alone in the hospital with a 
five-part fracture in her left leg, she 
had no one to call save one former 
lab mate. Although 
the injury has left her 
limping 11 years and 
two surgeries later, 
she hasn’t missed a 
step.
Baumgarth came to 
California by way of 
Germany, the UK, and 
Australia. It was in 
Brisbane that she first 
got her hands on influ-
enza, a virus of which 
she admiringly says 
elicits a nearly perfect 
immune response. In 
1996 she moved to 
Stanford to work with Leonore Her-
zenberg on B cell responses to influ-
enza (1). Now an associate professor at 
the University of California, Davis, 
Baumgarth finds herself back in a vet-
erinary school environment. There, 
she takes a nontraditional approach to 
looking at how the body protects itself 
from various pathogens that plague 
society today. Besides influenza, that 
list includes Lyme disease, malaria, 
HPV, and HIV (2). She puts B cells 
above all else academic, focusing on 
the innate regulation of antibody pro-
duction in response to infection 
(3–6).
NOVEMBER, TIME FOR THE FLU 
SHOT
With fl  u season upon us, I thought I 
might solicit a little free advice. Do you, 
an expert in infl  uenza, get the fl  u shot?
I get the shot now that I have two little 
kids. Before I had kids, I didn’t do it. I 
thought, “I’m a healthy, middle-aged 
person, I’m not going to die from the 
fl  u.” But now I’m more worried about 
giving it to my kids.
So you think fl  u vaccines work?
When the vaccine works, it works great. 
Last year, though, it didn’t work because 
it wasn’t perfectly matched [to the prev-
alent virus strain].
How might your research on infl  uenza 
help create a better fl  u vaccine?
One focus of my lab is to look at the 
cells that make broadly reactive anti-
bodies to all sorts of diff  erent patho-
gens in a nonspecifi  c way. We want to 
see if we can use the properties of these 
antibodies in a vaccine approach to ei-
ther increase their numbers or to make 
them go to the site where they’re 
needed for protection.
Taking advantage of a nonspecifi  c, innate 
response sounds quite diff  erent from most 
of today’s vaccines. What makes these 
natural antibodies so attractive?
At Stanford we found that you need 
the natural antibodies to be protected 
from flu. If you don’t have them, the 
virus will replicate faster; it’s one of 
the things that can keep the initial in-
fection in check. When we first looked 
at natural antibodies in the serum, 
nothing happened—the serum anti-
body levels stayed the same before and 
after the infection. Then when I start-
ed my own lab, I thought maybe it 
was because we had looked in the 
blood. The [influenza] infection actu-
ally occurs in the respiratory tract, not 
in the blood. So we looked in the re-
spiratory tract, and we saw that the B1 
cells accumulate there after infection. 
The interesting thing is that these cells 
are no more or less antigen specific 
than they were before infection…
there is no expansion of a specific re-
sponse, none of the things you associ-
ate with an adaptive immune response. 
We think an innate signal is driving 
these cells to the site of infection. We 
are now trying to find out the identity 
of the innate signal.
How might natural antibodies be used to 
fi  ght the fl  u?
Nobody has a problem with CD4, 
CD8, Th17, or Th2, but when people 
think of the B cell response they think, 
“Oh, they are just antibodies.” What I 
would like to convince the world of is 
that, like T cells, you have diff  erent B 
cell subsets that respond in diff  erent 
ways. B1 cells provide another level of 
protection. We have all this knowledge 
about protein-specifi  c antibodies. But 
if we knew what makes an antibody 
Baumgarth has had a long-standing love affair with T’s less popular cousins, 
the B cells. She holds high hopes for B1 cells in particular. Could they lead to a 
better vaccine?
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“If we knew 
what makes an 
antibody 
broadly 
reactive, we 
might not have 
to be so 
specific with 
vaccines.”
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broadly reactive we might not have to 
be so specifi  c with vaccines.
If you have an outbreak of something 
and you don’t know what it is, you can’t 
just vaccinate people—what would you 
vaccinate with? But what if you could 
stimulate antibody from the innate im-
mune system? Or stimulate B1 cells to mi-
grate to the respiratory tract if you knew 
there was a respiratory infection? This 
wouldn’t cure the disease and it might not 
even prevent infection, but it would buy 
you a few days during which your adap-
tive immune system could be activated. 
The fact that there is a B1 cell response to 
flu infection means we might be able to 
mimic that response with a vaccine or 
therapeutic. I’m excited about that.
What has to happen before the 
development of a nonspecifi  c fl  u vaccine 
can begin?
The big challenge is to fi   nd ways to 
track them [B1 cells], because if you 
want to make a vaccine that stimulates 
these cells you need to be able to moni-
tor them. Once we can do that we can 
ask questions like: Are people less pro-
tected from mutated viruses because 
they don’t have enough of the natural 
antibody? That’s so crucial.
AN ORGANISMAL 
IMMUNOLOGIST
You went to vet school in Germany, but 
you say you’ve always wanted to be in 
research. Has your veterinary background 
infl  uenced your work today?
When I started, there wasn’t this focus 
on the larger context. But my clinical 
background made me want to look at 
the whole picture. When you look at 
what I’ve done, there is always a focus 
on the whole pathological process of 
an infection.
I wish more people would think 
about the immune system as a whole 
system. There is an emphasis on 
mechanisms and molecular analyses, 
but at the end of the day all the mech-
anisms work together. I get frustrated 
when I hear people saying that one 
arm of the immune system isn’t im-
portant in this disease and another 
arm isn’t important in that disease; 
they’re all important. They all act to-
gether. In a given disease process one 
might be stronger, but at the end of 
the day they act together and that 
[complexity] drives a lot of what I do. 
Although I study B cells, I’m very 
aware of dendritic cells and NK cells 
and other [components of the im-
mune response]. 
This is what I try 
to teach my stu-
dents; it needs to 
fit together. If 
you can’t make 
these components 
fit together then 
it’s probably not 
going to work 
like that in vivo.
Is being at UC 
Davis, known as a 
bit of a farm-school, 
refreshing?
The reason I’m 
here is because 
UC Davis has one 
of the best vet 
schools in the 
country. So when I was applying for 
jobs it was appealing to get back to 
where I originally came from. During 
my vet degree, I was always very frus-
trated that there was so little emphasis 
on original research, so I thought I 
could be a role model for the few stu-
dents in these programs who want to 
do what I did. When I joined, UC 
Davis had just created a 
center for comparative 
medicine. The idea was 
that you’d have a mix of 
people with MDPhDs, 
straight PhDs and DVM-
PhDs that all work to-
gether in a center focused 
on animal models of 
disease.
What is your favorite 
molecule and why?
Can it be a cell?
Sure.
B cells. Nobody may 
agree with me. I’ve loved 
B cells for as long as I 
can remember. In high 
school in Germany, bi-
ology was one of my 
majors and there were four topics to 
choose from. I didn’t know what im-
munology was but I chose it anyway. 
When I learned about antibody pro-
duction…there was just something 
about it, I just loved it. I had to work 
on T cells for four years, but the mo-
ment I could, I switched back to B 
cells. I don’t know why. Bizarre.
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A plasma B cell (brown) spotted in the lymph node of a mouse 
produces virus-specific antibodies seven days after 
influenza infection.
"I get 
frustrated 
when I hear 
people saying 
that one arm 
of the immune 
system isn’t 
important in 
this disease 
and another 
arm isn’t 
important in 
that disease; 
they’re all 
important."